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Abstract
Metabolism is central to cell physiology, and metabolic disturbances play a role in numerous disease states. Despite its
importance, the ability to study metabolism at a global scale using genomic technologies is limited. In principle, complete
genome sequences describe the range of metabolic reactions that are possible for an organism, but cannot quantitatively
describe the behaviour of these reactions. We present a novel method for modeling metabolic states using whole cell
measurements of gene expression. Our method, which we call E-Flux (as a combination of flux and expression), extends the
technique of Flux Balance Analysis by modeling maximum flux constraints as a function of measured gene expression. In
contrast to previous methods for metabolically interpreting gene expression data, E-Flux utilizes a model of the underlying
metabolic network to directly predict changes in metabolic flux capacity. We applied E-Flux to Mycobacterium tuberculosis,
the bacterium that causes tuberculosis (TB). Key components of mycobacterial cell walls are mycolic acids which are targets
for several first-line TB drugs. We used E-Flux to predict the impact of 75 different drugs, drug combinations, and nutrient
conditions on mycolic acid biosynthesis capacity in M. tuberculosis, using a public compendium of over 400 expression
arrays. We tested our method using a model of mycolic acid biosynthesis as well as on a genome-scale model of M.
tuberculosis metabolism. Our method correctly predicts seven of the eight known fatty acid inhibitors in this compendium
and makes accurate predictions regarding the specificity of these compounds for fatty acid biosynthesis. Our method also
predicts a number of additional potential modulators of TB mycolic acid biosynthesis. E-Flux thus provides a promising new
approach for algorithmically predicting metabolic state from gene expression data.
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Introduction
Metabolism is central to cell physiology and metabolic disturbances
play a role in numerous disease states. Despite its importance, the
ability to study metabolism at a global scale using genomic technologies
is limited. In principle, complete genome sequences describe the range
of metabolic reactions that are possible for an organism, but cannot
quantitatively describe the behaviour of these reactions. Gene
expression data provide global insight into the regulation of metabolic
reactions, but methods for inferring the behaviour of metabolic
networks, and particularly metabolic flux, from these data are limited.
There is thus a need to develop computational approaches that utilize
available genomic data to make inferences about metabolism at the
level of large scale metabolic networks.
One approach to computationally studying metabolism is to
develop detailed models based on coupled differential equations
describing the dynamics of enzyme action. Such models, however,
require measuring numerous kinetic parameters that can be
prohibitively difficult for large systems and for organisms – such as
infectious disease agents – that are difficult to work with
experimentally.
Flux balance analysis (FBA) is an alternative approach to
modeling metabolism without developing detailed simulation
models that include enzyme kinetics [1–4]. It exploits the fact
that the stoichiometries of metabolic reactions are not organism-
dependent but are fixed by chemistry and mass balance.
Moreover, the availability of complete genome sequences is
enabling the reconstruction of metabolic networks whose constit-
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also exploits the fact that enzyme dynamics occur quickly
compared, for example, to regulatory changes in gene expression:
when the relevant laboratory time period (often hours) is much
longer than the chemical reaction times (typically minutes),
transient dynamics last for only a small portion of time period
considered, after which the metabolic network functions at steady
state. FBA is a method for utilizing universal reaction stoichiom-
etries to predict a network’s capability to produce a metabolic
objective under steady-state conditions.
Briefly, FBA represents a metabolic network by capturing the
stoichiometries of constituent reactions in a stoichiometric matrix,
S, and describing a flux configuration as a set of rates at which the
reactions in a network are moving (ie the set of reaction fluxes).
FBA requires that constraints for some reactions be known,
reflecting their maximum or minimum rates. These constraints
can either be measured (e.g. uptake reactions) or calculated from
physical parameters (e.g. oxygen diffusion) or thermodynamic
constraints. In many cases, the constraints can be related to the
degree of enzymatic activity for the given reaction. The matrix S
and the set of reaction constraints define the set of all possible flux
configurations at steady state. A flux configuration can be
visualized as a vector in flux space, and all flux configurations
that are feasible at steady state lie within a cone in this space,
called the flux cone. The core approach of FBA is to choose a
metabolic objective which is a linear function of fluxes, and then
use linear programming to optimize this objective subject to the
constraints. The algorithm results in one or more flux configura-
tions that are optimal for the chosen metabolic goal, and the
optimal production capacity of that objective.
FBA provides a method for exploring capabilities and states of a
metabolic system at steady state, and genome scale metabolic
models can be reconstructed based on annotated genome sequences
coupled with literature curation [1,2]. FBA has been used to
successfully predict the metabolic phenotype of gene knockouts [1–
3], and the use of metabolic modeling in this case has the advantage
of predicting nutrient-dependent phenotypes. FBA has also been
used to predict the time courses of growth, substrate uptake, and
metabolite production by both Escherichia coli and Mycobacterium
tuberculosis using a pseudo-steady-state dynamic modeling approach
[4–6]. FBA has recently been used as part of an integrated analysis
scheme for drug identification; there is a recent publication
(targetTB) by Raman et al. that reports this approach [7].
While powerful, FBA is limited in that it does not take into
account the gene regulatory state, as described for example by
gene expression data. In effect, the basic approach predicts
metabolic capabilities assuming all reactions have the same
maximum capacity. Indeed, many of the errors in the prediction
of gene knockout phenotype were traced back to the lack of gene
regulation in standard FBA models [1,2]. Incorporating a Boolean
model of gene regulation with FBA allows the prediction of more
biologically realistic dynamic behaviour, including for example a
diauxic shift in response to changing carbon source availability [8].
However, this approach reduces gene expression to Boolean
variables, using either a constant value or 0 for the upper flux
bound, rather than making use of direct measurements of gene
regulation through whole cell expression data.
We have developed a method, which we call ‘‘E-Flux’’, to
predict metabolic capacity based on expression data. E-Flux
extends FBA by incorporating gene expression data into the
metabolic flux constraints. We applied E-Flux to M. tuberculosis (M.
tb), the pathogen that causes tuberculosis (TB). An estimated one
third of the world’s population has been exposed to this disease,
which is estimated to kill 1.6–1.8 million annually worldwide.
Multiple drug resistant (MDR) and extensively drug resistant
(XDR) strains of tuberculosis are emerging worldwide, so the
development of new drugs is of the essence. Bacterial metabolism
plays an important role in TB pathology, both in terms of
metabolic alterations associated with intracellular growth [9–12]
as well as through the production of metabolic products associated
with virulence – including mycolic acids [13–15]. Given M. tb’s
slow growth rate, the hazards of experimenting directly with this
infectious organism, and limitations in measuring all metabolites
simultaneously, there is considerable motivation to augment
experimental approaches with computational methods for pre-
dicting M. tb metabolism.
Weused E-Flux topredict the impactofdrugsand environmental
conditions on mycolicacid biosynthesiscapacity inM. tb, based on a
compendium of expression measurements from these conditions.
Our method successfully identifies seven of the eight known
inhibitors of mycolic acid or fatty acid production that were present
in the compendium. E-Flux also correctly predicts whether
conditions are directly inhibiting mycolic acid production, or
inhibiting production indirectly through other mechanisms. Our
method thus provides a promising approach to modeling metabolic
state from whole cell measurements of gene regulation.
Results
Method Overview
The key innovation underlying the E-Flux approach is that we
use expression data to model the maximum possible flux through
metabolic reactions. When the expression for a particular enzyme-
coding gene is low (relative to some reference), we place a tight
constraint on the maximum flux through the corresponding
reaction(s). When expression is high we place a looser constraint
on the flux through the reaction(s). We then use FBA with the
applied constraints and an appropriate objective function to
determine a corresponding metabolic state or optimal metabolic
capacity.
Conceptually, our method can be understood as setting the
width of ‘‘pipes’’ around particular reactions as a function of
Author Summary
The ability of cells to survive and grow depends on their
ability to metabolize nutrients and create products vital for
cell function. This is done through a complex network of
reactions controlled by many genes. Changes in cellular
metabolism play a role in a wide variety of diseases.
However, despite the availability of genome sequences
and of genome-scale expression data, which give infor-
mation about which genes are present and how active
they are, our ability to use these data to understand
changes in cellular metabolism has been limited. We
present a new approach to this problem, linking gene
expression data with models of cellular metabolism. We
apply the method to predict the effects of drugs and
agents on Mycobacterium tuberculosis (M. tb). Virulence,
growth in human hosts, and drug resistance are all related
to changes in M. tb’s metabolism. We predict the effects of
a variety of conditions on the production of mycolic acids,
essential cell wall components. Our method successfully
identifies seven of the eight known mycolic acid inhibitors
in a compendium of 235 conditions, and identifies the top
anti-TB drugs in this dataset. We anticipate that the
method will have a range of applications in metabolic
engineering, the characterization of disease states, and
drug discovery.
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model with 4 metabolites and 4 internal reactions catalyzed by
enzymes corresponding to 4 genes, together with an uptake
reaction and a reaction converting one metabolite into biomass.
Two different sets of simulated gene expression data are shown in
the two panels. In the top panel, G1 is poorly expressed. Our
method models this conceptually as a thin pipe around reaction 1,
limiting the maximum flux through this reaction. Conversely, in
the bottom panel, G1 is highly expressed corresponding to more
possible flux (a wider pipe). Under conditions in which substrate is
not limited, we would predict more flux through reactions 3 and 4,
and less through reactions 1 and 2 in the top panel. Conversely, we
might predict more flux through reactions 1 and 2, and less
through 3 and 4, in the bottom panel.
Geometrically, setting maximum flux constraints according to
gene expression reshapes the flux cone. Different gene expression
states result in different flux cone geometries, which can lead to
different solutions for the same metabolic objective. Reshaping the
flux cone and thus generating different flux configurations is
similar to the approach used to predict phenotypes from gene
knockouts using FBA [1–3] and for coupling Boolean regulatory
models with metabolic models [8]. However, such approaches
have used constraints that are the same for all reactions except
those that are turned off. By contrast, E-Flux shapes the cone not
by turning individual genes on or off, but by giving many or all
genes in the model a range of possible flux limits. More
importantly, we are reshaping the flux cone on the basis of
empirical measurements of gene expression.
Our method does not assume that enzyme concentrations,
enzyme activities, or realized reaction fluxes are determined by
mRNA expression values. Indeed, the true flux for a reaction
depends on the enzyme kinetics and concentration, as well as the
concentration of metabolites. The effective enzyme concentration in
turn depends on gene expression, transcription and translation, post-
translational modification and degradation. It would be prohibitive
to determine these values for many reactions in an organism.
However, the biological rationale behind our method is that
expression data provide measurements on the level of mRNA for
each gene. If there were limited accumulation of enzyme over the
time course considered, and given a particular level of translational
efficiency, the level of mRNA can be used as an approximate
upper bound on the maximum available protein and hence as an
upper bound on reaction rates to some level of approximation.
This allows us to extend flux balance analysis from an algorithm
that assumes that all reactions have the same constraint, as has
been done previously, to an approach making use of condition-
dependent, empirical data. E-Flux allows us to link such data
directly to changes in metabolic capability. We discuss rationale
behind our method further in the Discussion.
Mathematically, our approach modifies FBA as follows. FBA
involves solving the following optimization problem:
max
v
cTv
subject tof
S:v~0
ajƒvjƒbj
ð1Þ
where v is a flux vector representing a particular flux configura-
tion, S is the stoichiometric matrix, c is a vector of coefficients that
defines a linear objective function c
Tv, and aj and bj are the
minimum and maximum fluxes through reaction j. We assume
that we have a set of expression measurements for some or all of
the genes associated with the reactions in S.
The core E-Flux method chooses the maximum flux, bj, for the
j
th reaction according to a function of the expression of gene j and
associated genes:
bj~f(expression level of genes associated with reaction j) ð2Þ
If the reaction catalyzed by the corresponding enzyme is reversible
then aj=2bj, otherwise aj=0. For the results presented here,
Figure 1. Illustration of E-Flux method. The core idea of the method is that we use gene expression to set maximum flux constraints on
individual reactions. This can be illustrated as pipes of different widths around each reaction. Here we show a simple model comprised of 4
metabolites (A–D), 4 internal reactions, an uptake reaction for A, and a reaction converting D to biomass. On the left are simulated gene expression
data for 4 genes whose enzymes catalyze the 4 internal reactions (green – lower expression, red – higher expression). In the top panel, G1 is poorly
expressed; this can be conceptualized as a thin pipe around reaction 1 as shown. In the bottom panel, G1 and G2 are highly expressed,
corresponding to a wider pipe for these reactions. Under conditions in which uptake of A is not limiting, we would predict more flux through R1 and
R2 in the bottom panel relative to the top panel and R3 and R4. This is shown by the bars on the right. The specific conditions giving rise to the
qualitative predictions on the right are given in the Methods section.
doi:10.1371/journal.pcbi.1000489.g001
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same enzyme complex, and genes associated with separate
isozymes of the reaction. In the latter case, we choose f to be a
monotonically increasing function of the expression of the
corresponding genes. In general bj can also depend on genes that
modulate the activity of the enzyme for reaction j and f can thus
take on a more general form. In the Discussion section, we
examine the question of which genes to associate with a particular
maximum flux constraint and the functional form of f.
Application of E-Flux to M. tuberculosis Mycolic Acid
Biosynthesis
We tested E-Flux on two metabolic models that include the
biosynthesis of mycolic acids in M. tb. The first model consisted of
just those reactions underlying mycolic acid production. Mycolic
acids are cell wall components characteristic of mycobacteria and
essential for the survival of the bacterium [13]. Because the
mycolic acid biosynthetic pathway does not exist in non-
actinmycetales species, including humans, it is the target of several
of the most common antibiotics used to treat TB including
isoniazid, thiolactoymycin and ethionamide. Moreover, a meta-
bolic sub-model for this pathway has been previously published
[7]. This model, which included 28 proteins, 219 reactions and
197 metabolites, contained four sub-pathways representing the
production of malonyl CoA, the fatty acid synthase (FAS) I and II
pathways, and the condensations of the resulting FAS products
into alpha-, methoxy- and keto- mycolic acids. We augmented this
model with two additional genes subsequently identified with
mycolic acid biosynthesis [16].
We analyzed the microarray data from the Boshoff TB gene
expression compendium [17]. This compendium consists of data
from several studies, totalling 437 microarray experiments which
measured the transcriptional response of M. tuberculosis to 75
different substances and conditions, including known anti-
tubercular drugs, growth conditions and unknown compounds.
Specifically, this set also included eight known inhibitors of
mycolic acid production. Our goal was to use E-Flux to predict the
impact of each of these compounds or conditions on mycolic acid
biosynthetic production in M. tuberculosis.
To explore the method’s relevance to data from diverse groups
and for a variety of experimental conditions, we also analyzed a set
of expression data of Karakousis et al. [18]. These authors
analyzed global gene expression profiles to study the action of
isoniazid, a mycolic acid inhibitor and front-line antitubercular
agent, on several models of M. tb’s dormancy phase.
Application to Genome Scale M. tuberculosis Metabolic
Model
Two genome-scale metabolic models are available for M.
tuberculosis, namely those of Beste et al. [6] and Jamshidi and
Palsson [19]. To validate that our method scales to genome-wide
metabolic model, we applied E-Flux to the comprehensive model
of M. tuberculosis metabolism of Beste et al. [6]. This was chosen
because the model contains more genes and the predictions for
gene essentiality were better than those of Jamshidi and Palsson,
whose focus was more on growth rates. Since our analysis is
comparative in nature we felt that the qualitative advantage of a
model with more correct gene essentiality was relevant.
Beste et al.’s model [6] was modified by merging this genome
scale model with the mycolic acid submodel of Raman et al. [7].
Specifically, we removed mycolic acid reactions from the genome-
scale model and replaced them with the mycolic acid reactions in
Raman et al.’s model, and normalized the bounds on exchange
reactions (see Methods and Supplementary Material for more
details). The net result was to replace Beste et al.’s representation
of mycolic acids with that of Raman et al., as the latter is more
detailed and as this allows direct comparison of the results of E-
Flux in the two models.
As with the model of mycolic acid production, we applied E-
Flux to the genome scale model to predict the impact of each of
the compounds or conditions in the Boshoff TB gene expression
compendium on mycolic acid biosynthetic production [17].
Computational Approach
Our computational approach is shown in Figure 2. We first pre-
processed the expression data using a previously published analysis
of variance (ANOVA) method [20]. This method utilizes replicates
within and between conditions to estimate sources of noise
including variations between binding affinities at different spots on
each chip, variations from chip to chip, various binding affinities
from gene to gene, dye effects, and biological variation within
replicates. We also performed the method using data pre-
processed with a median-adjustment to the control channel
median of each chip. Our predictions were not substantially
altered by the choice of pre-processing.
Following pre-processing, we separated the drug or condition
(cy5) and control channels (cy3). For each experiment we first
applied expression data from the control channel to set constraints
on maximum fluxes of reactions in the model. We then used FBA
to find a flux configuration that maximized overall mycolic acid
biosynthesis (bottom light blue bar in Figure 2). Similarly, we
predicted maximum mycolic acid production for the correspond-
ing drug condition by applying expression from this channel
(bottom red bar). We compared both predictions to assess the
relative impact of the drug or condition on mycolic acid
biosynthetic capacity (right blue bar). In the case of Figure 2, we
would predict that the drug inhibits mycolic acid production.
To perform FBA for the mycolic acid biosynthetic model, we
utilized an objective function representing total mycolic acid
production. This model does not suggest that M. tb is in fact trying
to maximize production of mycolic acids, but this objective
function allows us predict the maximum amount of mycolic acid
the model could produce under the given constraints. For the
genome-scale model, we used the same objective function. We
were also able to use the biomass objective as given in [6]
(Methods).
Differences in predicted mycolic acid flux arising from
comparing the drug and control channel could arise due to
fluctuations in gene expression measurements independent of drug
effects. To determine whether a particular difference could be
explained by such fluctuations, we resampled data on the control
channels with noise fluctuations derived from the ANOVA
analysis to understand how much variation in the predictions
would result from comparing two different control channels. The
95% confidence interval for predictions from resampled control
channel data is represented as the dotted lines in Figure 3 and is
the same for all experiments. To generate error bars for each
prediction we resampled both control and drug channels with
noise drawn from this distribution; the resulting error bars are
shown in Figure 3.
We also wished to determine if predicted differences were
specific to mycolic acid biosynthesis or reflected a more general
change in metabolism. For example, a predicted inhibition of
mycolic acid production might be due to an overall suppression of
gene expression or metabolism. To this end, we randomly
relabelled genes within each data set and found predictions using
E-Flux. Repeating this permutation and computation multiple
Interpreting TB Expression with Flux Models
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effects on mycolic acid production for each condition. The 95%
ranges for these distributions are shown as grey bars in Figure 3.
Predicted Mycolic Acid Biosynthesis Modulators
We applied the approach shown in Figure 2 to all 437
experiments in the Boshoff data set. The results for the mycolic
acid biosynthetic model are summarized in Tables 1 and 2 and
details for a subset of predictions are shown in Figure 3. The most
noteworthy aspect of these results is that of the eight known
inhibitors of mycolic acid tested in the Boshoff data set, E-Flux
correctly predicts seven. More generally E-Flux identifies as
modulators all of the drugs used against tuberculosis that are
known to affect the mycolic acid pathway.
The application of E-Flux to the the M. tb genome-scale model
produced an identical set of predicted inhibitors and enhancers
with the same specificity and predicted strength as those in Table 1
and Table 2 although the quantitative predictions differed slightly
(Supplementary Material). This was true regardless of whether we
used the mycolic acid objective function from [7] or the biomass
objective function of [6]. Our method is thus applicable to the
both targeted metabolic models as well as genome-scale metabolic
reconstructions.
The strongest predicted inhibitors included isoniazid (INH) and
ethionamide. Isoniazid, a first-line drug for TB, is a prodrug that is
activated by the bacterial catalase-peroxidase enzyme KatG [21].
Activation leads to the development of INH-NAD and INH-
NADP adducts that inhibit InhA and FabG1 respectively [22,23].
Both InhA and FabG1 are components FAS-II cycle of mycolic
acid biosynthesis [22,24]. Ethionamide is a structural analog of
INH and is thought to also target InhA [25]. Both isoniazid and
ethionamide are predicted as strong selective inhibitors of mycolic
acid biosynthesis.
E-Flux also predicts thiolactomycin and ethambutol as strong
selective inhibitors. Thiolactomycin is a natural product produced
by both Nocardia and Streptomyces and is a potent and highly
Figure 2. Applying E-Flux to mycolic acid biosynthesis. For each experiment from [17], we separated the corresponding drug or condition
(cy5) and control channels (cy3). When first applied expression data from the control channel to set constraints in the mycolic acid model (the model
schematic is adapted from [7]) and used FBA to predict maximum mycolic acid biosynthetic capacity (bottom light blue bar). We then predicted
maximum mycolic acid flux for the drug by applying expression from this channel (bottom red bar). We compared both predictions to assess the
relative impact of the drug or condition on mycolic acid biosynthetic capacity (right blue bar). The dotted lines on the right indicate 95% confidence
intervals for differences that would be expected from comparing two control channels. The barbells represent condition specific error bars. A similar
method was used for the genome scale model (Methods).
doi:10.1371/journal.pcbi.1000489.g002
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plants and bacteria [26]. Ethambutol inhibits the arabinosyl
transferases in the synthesis of arabinogalactan, and prevents the
attachment of mycolic acids to the 59-hydroxyl groups of D-
arabinose residues of arabinogalactan thus obstructing the
formation of the mycobacterial cell well [27]. Interestingly, E-
Flux only predicted inhibition for the highest concentration of
ethambutol. If correct, this mechanism may lead to reduced
quantities of mycolate polymer, with subsequent build-up of free
mycolate, and it seems possible that mycolic acid biosynthesis
would be down-regulated in response.
In addition, E-Flux predicts a number of weaker inhibitors,
including two drugs known to impact mycolic acid. Cerulenin is a
fungal mycotoxin that is known to inhibit both FAS-I and FAS-II
cycles in mycolic acid synthesis in M. tb [28]. Pyrazinamide is a
pro-drug of pyrazinoic acid, and inhibits the FAS1 pathway of
mycolic acid synthesis in M. tb [29]. PA-824 is a newer
nitroimidazopyran drug currently in clinical trials [30]. PA-824
inhibits both lipid and protein synthesis by as yet unknown
mechanisms. E-Flux predicts that PA-824 inhibits mycolic acid
synthesis at the higher concentration replicates but not at lower
ones. PA-824 was not predicted as a specific inhibitor of mycolic
acid biosynthesis, although this may be due to the additional effect
of PA-824 on protein synthesis genes or to the relative weakness of
the predicted mycolic acid inhibition.
E-Flux also predicts several novel compounds not previously
associated with inhibition of mycolic acid biosynthesis. These
include predictions of weak effects for the protein synthesis
inhibitor streptomycin and the ionophore valinomycin. These
compounds are predicted as non-specific inhibitors consistent with
an overall impact on metabolism. PA-21 was also predicted to be a
weak and marginally specific inhibitor, although the mechanism of
Figure 3. Selected predictions of E-Flux applied to mycolic acid biosynthesis in M. tuberculosis. Top panel: predictions and prediction
significance are displayed for each condition as described in Figure 2. Conditions are arranged on the x-axis as indicated by the labels. Many
conditions are replicates of the same compound, possibly with different concentrations. Replicates are indicated by the background shading and
brackets in the horizontal axis label. Numbers in the brackets are concentrations for each replicate. Bottom panel: the specificity of each prediction
for mycolic acid biosynthesis is displayed. The dark bars indicate the prediction strength as in the top panel. The light grey bars indicate the 95%
confidence interval for predictions made by randomizing gene labels. Dark bars smaller than light bars indicate non-specific predictions. Known fatty
acid inhibitors are shown as red on the horizontal axis label.
doi:10.1371/journal.pcbi.1000489.g003
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inhibitors, only ZnSO4 was predicted to have a strong effect with
marginal specificity. However, only a single replicate for ZnSO4 is
present in the Boshoff data set, and preliminary experimental data
suggest that this prediction is likely a false positive.
Interestingly, E-Flux also predicted a small number of
compounds that may enhance fatty acid biosynthesis. Menadione
and chlorpromazine are predicted to be weak non-specific
enhancers, although these results are convolved with GSNO and
one instance of GSNO in isolation was predicted as a strong and
specific enhancer. However, it is noteworthy that menadione has
been reported to increase fatty acid production in human fat cells,
in addition to a number of other metabolic effects [31].
Chlorpromazine is a phenothiazine, a class of compounds recently
proposed as possible drugs targeting multi-drug resistant tubercu-
losis. GSNO is a nitric oxide donor toxic to mycobacteria [32]
whose mechanism of antimycobacterial action of GSNO is
unknown [33,34]. Extracellular glutathione is converted to a
dipeptide, which is transported into the bacterial cells by the
multicomponent ABC transporter dipeptide permease [32].
Curiously, triclosan was also predicted as an enhancer.
Triclosan is known to inhibit the enoyl-ACP reductase of FASII
[35]. Although we predict no significant effect at low concentra-
tions, E-Flux predicts a significant upregulation of mycolic acid
production at the highest concentration. It has been observed that
triclosan acts through more than one mechanism [35] and may
lead to upregulation of fatty acid metabolism
The data of Karakousis et al. [18] on the transcriptional
response of dormant M. tb to isoniazid provide the opportunity to
examine the predictions of E-Flux for dormant tuberculosis.
Though it is a strong inhibitor of mycolic acid biosynthesis,
isoniazid has little activity against M. tb under oxygen deprivation
or nutrient starvation [36]. Consistent with this, Karakousis et al.
[18] found that the transcriptional signature associated with
isoniazid’s activity in non-dormant tuberculosis was abolished
under conditions of dormancy. The results of E-Flux applied to
these data are shown in Figure 4. E-Flux correctly shows a strong
and significant inhibition of mycolic acid biosynthesis after
6 hours, but shows no effect of isoniazid for any of the four
dormancy models in the dataset. This not only confirms the result
for isoniazid from the Boshoff compendium [17] but provides an
indication that E-Flux may be a useful tool in analyzing expression
profiles for dormant M. tb under a range of treatment conditions,
when such data become available.
Comparison to Gene Expression Clustering
To rule out that our predictions reflect similarities in gene
expression independent of metabolic modeling, we clustered the
expression of the 29 genes used in the mycolic acid biosynthetic
model across all 437 experiments in the Boshoff data set. As can be
seen in Figure 5, known inhibitors do not form a single cluster.
This is consistent with the results of clustering all M. tb genes as
reported by Boshoff et al. [17]. Similarly, inhibitors and enhancers
predicted by E-Flux also do not form a single cluster. Furthermore,
predicted inhibitors do not obviously fall into clusters with
previously known inhibitors, suggesting that using a metabolic
model allows the discovery of distinct routes to inhibition or
Table 1. Summary of E-Flux predicted mycolic acid inhibitors
from Boshoff data set.
Predicted Inhibitors
Isoniazid Specific Strong Known
Thiolactomycin Specific Strong Known
Ethionamide Specific Strong Known
ZnSO4 Non-specific Strong New
Ethambutol Specific
{ Weak
{ Known
Cerulenin Specific
{ Weak
{ Known
PA-21 Specific
{ Weak New
Streptomycin Non-specific Weak New
Valinomycin Non-specific Weak New
Amikacin Non-specific Weak
{ New
Pyrazinamide *
{ Non-specific Weak Known
Tetracycline Non-specific Weak New
Dubos-NRP1; Dubos-NRP1+KNO3 Non-specific Weak* New
PA-824 Non-specific Very weak Known
Chlorpromazine
{ Non-specific Very weak New
Capreomycin Non-specific Very weak New
Synthetic pyridoacridine analog
(124196)
{
Specific Very weak New
Ascedidemin (111895)
{ Non-specific Very weak New
Rifapentine
{ Non-specific Very weak New
Procept 6776, 6778
{ Non-specific Very weak New
Succinate, palmitate in minimal
medium*
Non-specific Very weak New
Starvation conditions Non-specific Very weak Expected
Results are shown for all significant predictions from the set of 437 experiments
in Boshoff et al [17]. Of the seven known inhibitors of fatty acid biosynthesis, E-
Flux correctly predicts 6. Strong effects are defined as effects showing greater
than +/23 log change between control and drug; weak inhibitory effects have
inhibition less than 21.5 log change and very weak effects less than 21. Weak
enhancing effects have greater than +1 log change. Specific effects indicate
effects on mycolic acid biosynthesis as contrasted to effects over a broad range
of pathways – see text for more details.
*Prediction made only for certain replicates.
{Prediction made only for certain doses.
Starvation conditions were phosphate- or Tris-buffered saline containing 0.05%
Tween 80 (PBST or TBST) [17]. Conditions with both enhancing and inhibiting
predictions among replicates were excluded.
doi:10.1371/journal.pcbi.1000489.t001
Table 2. Summary of E-Flux predicted mycolic acid enhancers
from Boshoff data set.
Predicted Enhancers
Chlorpromazine/GSNO Non-specific Weak* New
Rifapentine
{ Non-specific Weak New
Rifampicin
{ Non-specific Weak New
Chlofazimine/GSNO Non-specific Weak New
GSNO Specific Strong* New
Menadione/GSNO Non-specific Very weak* New
Triclosan Non-specific Very weak* Incorrect?
Results are shown for all significant predictions from the set of 437 experiments
in Boshoff et al [17]. Strong effects are defined as effects showing greater than
+/23 log change between control and drug; weak enhancing effects have
greater than +1 log change, and we list two very weak effects defined as
prediction lying outside the 95% null confidence interval. Specific effects
indicate effects on mycolic acid biosynthesis as contrasted to effects over a
broad range of pathways – see text for more details.
*Prediction made only for certain replicates.
{Prediction made only for certain doses.
Conditions with both enhancing and inhibiting predictions among replicates
were excluded.
doi:10.1371/journal.pcbi.1000489.t002
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with known inhibitors. More fundamentally, in contrast to
supervised classification methods, E-Flux does not require data
from compounds with a known effect to calibrate the method (i.e.
an initial training set is not required). In particular, no mycolic
acid enhancers are currently known, and thus a method designed
to classify new enhancers by comparing expression profiles to
known compounds would not be applicable. We consider the
differences between E-Flux and expression classification in more
detail in the Discussion section.
Discussion
In this paper, we have presented a novel method for predicting
metabolic capacity from gene expression data. E-Flux extends flux
balance analysis to predict characteristics of steady state
metabolism that correspond to specific empirically-measured gene
expression states. The key innovation of our method is that we use
gene expression data to model the maximum flux through
individual metabolic reactions.
We have used E-Flux to predict the impact of drugs, drug
combinations, and environmental conditions on mycolic acid
biosynthetic capacity in M. tuberculosis, based on microarray data
from the Boshoff TB expression compendium. E-Flux correctly
predicts seven of eight inhibitors of mycolic acid biosynthesis within
this compendium, and correctly predicts the specificity of this
inhibition for mycolic acid biosynthesis in all but one case. E-Flux
also predicts a small number of additional potential inhibitors, as
well as potential enhancers of mycolic acid production. We also
tested E-Flux on data for dormant M. tb treated with isoniazid, and
it correctly predicts the difference in effect of this agent in several
dormancy models.
E-Flux thus provides a potentially powerful tool for exploring
metabolic state (which is relatively difficult to measure) from gene
expression state (which is relatively simple to measure in many
circumstances). This is particularly significant for tuberculosis
given the difficulty of working with M. tb, the availability of many
microarray experiments for this organism (www.tdbd.org), and the
essential role of metabolism in the pathogenesis of M. tb.
Gene Expression and Maximum Flux Constraints
The key principle underlying the E-Flux method is that mRNA
levels for enzymes approximate an upper bound on the potential flux
through the corresponding metabolic reactions, i.e. for a particular
level of translation and degradation, the amount of mRNA sets an
upper bound on the amount of available enzyme. The amount of
available enzyme is in turn proportional to maximum flux (e.g.
Vmax) through a particular reaction.
We acknowledge that mRNA expression is not sufficient to
determine fluxes or, in many cases, true upper bounds on fluxes,
but nonetheless argue that including mRNA expression data into
flux balance models provides a new and useful way to connect
expression data with models cellular metabolism, and is an
improvement upon effectively assuming that all reactions that are
present have the same maximum flux. The degree of correlation
between mRNA and protein levels is an area of ongoing research
[37]. There are conflicting reports regarding the correlation
between mRNA and protein levels [38], but some whole genome
studies have reported modest correlations. A study of 289 proteins
in Saccharomyces cerevisiae, for example, reported a correlation of
0.61 after correcting for methodological issues [39]. Correcting for
methodological noise and potential non-linearity in the mRNA-
protein relationship, however, results in higher levels of mRNA-
protein concordance [37,40,41]. In prokaryotes, ribosomes bind to
nascent mRNAs so that translation can be synchronous with
transcription; proteins levels thus depend more directly on mRNA
abundance [42]. Consistent with this, a comparison of Staphylococ-
cus aureus biofilm and planktonic cells showed qualitative
agreement between transcriptomic and proteomic expression
differences [43], and an analysis of mRNA and protein levels for
400 genes from Desulfovibrio vulgaris reported correlations between
0.45–0.53 [40,41]. In addition, genes from different functional
categories display different levels of correlation. For example, in
both S. cerevisiae and D. vulgaris genes associated with central
intermediary and energy metabolism display higher levels of
correlation than other groups [41], and a study of central
metabolism genes in both wildtype E. coli DF11and a pgi mutant
found a correlation of .81 between the log ratio of transcripts and
the log ratio of enzyme activities [44]. Studies of transcriptional
Figure 4. Predictions of E-Flux applied to data on M. tb’s response to isoniazid under dormancy conditions. Top panel: predictions
and prediction significance are displayed for each condition as described in Figure 2. Isoniazid shows a significant effect after 6 hours but shows no
comparable inhibition under dormancy conditions. Note that the lack of inhibitory effect shown at 2 hours may reflect incompleteness of the
transcriptional at this time, in which case the most relevant comparison is to the oxygen depletion condition (6 hr) showing no significant inhibition
for this dormany model. Bottom panel: the specificity of each prediction for mycolic acid biosynthesis is displayed. The dark bars indicate the
prediction strength as in the top panel. The light grey bars indicate the 95% confidence interval for predictions made by randomizing gene labels.
doi:10.1371/journal.pcbi.1000489.g004
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transcription-translation coupling. In unbranched segments of
amino acid biosynthetic pathways, genes for enzymes catalyzing
upstream reactions are transcribed earlier and with a higher
promoter activity than those for downstream reactions. This
pattern is optimal for rapidly producing end-products while
minimizing enzyme production when enzyme levels are a direct
function of mRNA levels.
Although the total amount of available enzyme sets an upper
limit on the maximum flux through a particular reaction, many
regulatory processes may modulate the effective levels of enzyme
activity. Metabolite feedback regulation, allosteric interactions,
Figure 5. Clustering of experiments in the Boshoff compendium using expression of the mycolic acid biosynthetic genes. Clustering
was performed with hierarchical clustering using pearson correlation for the distance metric and the average linkage method. Known mycolic acid
inhibitors do not cluster based solely on gene expression. This is consistent with the clustering of all M. tb genes reported by [17]. Similarly, predicted
inhibitors and enhancers do not form distinct clusters.
doi:10.1371/journal.pcbi.1000489.g005
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enzymes already synthesized. These modulations, however, cannot
lead to more activity than is possible if all available enzyme were
maximally active. For example, in the extreme case where an
enzyme is completely deactivated by covalent modification (e.g.
inactivation through phosphorylation), the true flux through a
reaction is zero whereas mRNA levels might suggest a higher
bound. With respect to E-Flux, this means that the upper bound
on enzyme activity set by mRNA levels is an upper bound, but not
always a tight one. In such a case, the accuracy of predictions
made by E-Flux may depend on the difference between the
approximate and true bounds.
It would be possible to generalize the E-Flux framework to take
modulation of enzyme activity into account. In our application to
mycolic acid production, we model maximum flux for a reaction
as a function of all genes that are components of the corresponding
enzymes or enzyme complexes. However, we could incorporate
the expression of all genes whose products modulate the activity of
a given enzyme into this function. For example, if an enzyme is
inactivated through phosphorylation by a kinase, we may choose
to model the corresponding maximum flux as a function of the
expression of the genes for both the enzyme and kinase. This
approach is conceptually similar to the coupling of metabolic
models with Boolean regulatory models taken by Covert et al.
[46], although E-Flux differs in that empirically measured gene
expression levels are used. Such an approach, however, would
require more knowledge of regulatory interactions between
proteins than we used in the analysis presented here.
Comparison to Previous Approaches
A number of previous methods have been developed to gain
insight into metabolism from expression data. The most common
method is to identify genes or sets of genes from particular
pathways that are differentially expressed under different condi-
tions [47,48]. Often this involves visualizing expression data on
metabolic maps [49]. Although useful, this approach is limited by
the need for the subjective interpretation of differentially expressed
gene sets, typically by an expert on the metabolic pathways of
interest.
Other methods have been based on classifying gene expression
by similarity to expression patterns corresponding to known
metabolic or cellular states [50–52]. In the case of mycolic acid
biosynthesis, however, different inhibitors do not cluster together
based on expression similarity, either when considering all M. tb
genes [17] or only the 29 genes directly involved with mycolic acid
synthesis (Figure 5). This is consistent with the range of
mechanisms by which mycolic acid biosynthesis can be sup-
pressed. For example, isoniazid, ethionamide, and thiolactomycin
inhibit the FAS-II fatty acid biosynthetic cycle, whereas cerulenin
inhibits both FAS-I and FAS-II, and ethambutol blocks the
incorporation of mycolic acids into the cell wall. It is possible that a
gene expression-based classifier could be developed that would
correctly identify inhibitors across this range of mechanisms. E-
Flux, however, implicitly integrates across these different mech-
anisms by interpreting expression data through the lens of a
metabolic network model.
More fundamentally, our method does not require a set of
training data whose effect on the pathway is known in advance.
Traditional classification methods require exemplars from the
categories to be classified [53]. These exemplars are used to select
a decision boundary in some space that places objects of one
category on a different side of the boundary from objects in other
categories. Although the Boshoff data set contained conditions
corresponding to known mycolic acid inhibitors, this information
was not used to parameterize our method. Instead, E-Flux uses a
model of the underlying chemical and biological network to
simulate the effects of different regulatory states. The method can
thus be used to classify new expression data sets even in the
absence of previous data from the same class. Moreover, we are
able to predict previously unreported effects. For example, our
method predicts that a small number of compounds may act to
increase overall mycolic acid production although no known
mycolic acid enhancers are included in the set. Furthermore, while
our goal here was to predict the metabolic impact of a known
external condition, in a related manuscript [54], we reverse this
logic to predict an unknown environment, in particular to identify
the most likely nutrient being metabolized, using expression data
coupled to metabolic models.
Since the initial development of E-Flux, two other methods for
combining expression data with flux balance analysis have been
described. The method of Becker and Palsson [55] utilizes a
variant of the method of Covert and Palsson [46] to turn genes on
or off. In contrast to this approach where genes were turned off
based on a Boolean model of gene regulation, the method of
Becker and Palsson [55] turns off genes whose expression is below
a given threshold level. If this constrained model is incapable of
achieving a given objective, genes are turned back on until the
objective is reachable. The method of Shlomi et al. [56] uses a
novel nested optimization method to determine an FBA solution
while also maximizing the correspondence between gene expres-
sion levels and metabolic fluxes. These methods differ with respect
to the degree that expression data is used to modulate constrains
on an FBA model. Becker and Palsson [55] apply a hard constraint
using gene expression such that genes are either on or off. On the
other hand, genes not turned off are not modulated by expression
data. Shlomi et al. [56], in contrast, use expression data to
influence fluxes indirectly, rather than through flux constraints. E-
Flux falls in the middle of these two approaches. It is more
aggressive than the method of Shlomi et al. [56] in that fluxes are
directly constrained by expression. It is less aggressive than the
method of Palsson et al. [55] in that genes are not turned off,
although more comprehensive in that all flux constraints are
modulated by the expression of the corresponding genes. Which
approach is more accurate likely depends on the application.
Other Applications of E-Flux
E-Flux provides a general approach for modeling metabolism
from expression data. This approach has a number of potential
applications, beyond the application to tuberculosis presented
here. E-Flux can also be used to investigate and model other
disease states where expression data are available and for which
metabolic alterations are associated. For example, many cancer
cells are known to grow glycolytically in the presence of oxygen
and to develop a lipogenic phenotype [57–59]. With the
availability of numerous expression data sets for various cancer
cells, E-Flux may provide an opportunity to study this phenom-
enon computationally.
E-Flux could in principle also be used as a tool for drug
discovery. For example, if a drug were sought that decreased
production of a particular metabolite, then genome-scale expres-
sion profiles of a large number of small molecules could be
analyzed with E-Flux and subsequent study could focus on those
for which E-Flux predicted the desired inhibition. This would be a
valuable approach in settings where screening directly for the
effect of interest is expensive relative to microarray analysis. In
addition, since E-Flux can predict unanticipated effects, the
approach could be used to predict possible undesirable effects
including the production of toxic metabolites. Furthermore, if a set
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different subsystem or pathway in the metabolic network, then E-
Flux could be used separately for each objective to help identify a
molecule’s mechanism of action.
Finally, E-Flux provides a new tool for efforts to engineer
metabolic systems. Flux analyses have been previously used to
guide the design of metabolic networks. E-Flux enhances this
approach by enabling the prediction of metabolic characteristics
for specific empirically determined gene expression states.
Materials and Methods
FBA Model of Mycolic Acid Biosynthesis
We used two metabolic models: a model of the mycolic acid
biosynthesis subsystem [7], and a genome-scale model for M.
tuberculosis [6]. The small subsystem model comprises four sub-
pathways: fatty acid synthase (fas) I and II, the production of
malonyl-CoA which is an input for each of these, and the
condensation of the products of fas I and II into alpha, methoxy
and keto mycolic acids. The model has 197 distinct metabolites,
linked together in 219 internal reactions. There are an additional
28 external reactions corresponding to uptake of the primary
input, AccB, the free exchange of water, carbon dioxide and other
substances not explicitly produced and consumed in the model,
and the production of the mycolate outputs. The model is
available in SBML format at DOI: 10.1371/journal.-
pcbi.0010046.sd001 and is presented in the supplementary
material of [7]. Two genes in the model remained unknown and
were labeled ‘UNK1’ and ‘UNK2’ at the time Raman et al.
published the mycolic acid metabolic model. One of these was the
gene or complex responsible for the dehydration of (3R)-
hydroxyacyl-ACP in the fas II elongation cycle in M. tuberculosis.
Subsequent to the publication of the orginal model by Raman et
al., Sacco et al. [16] identified two heterodimers, Rv0635-Rv0636
(HadAB) and Rv0636-Rv0637 (HadBC) which perform this role.
They observed substrate specificity for these dimers, with hadAB
preferentially catalyzing this reaction for shorter carbon chains
and hadBC doing so for longer carbon chains. We included
catalysis of reactions 68 and 74 (length up to C-18) by hadAB, and
reactions 80, 86, 92, … ,188 (longer lengths) by hadBC. Our
results were not substantially altered by including the hadABC
genes.
The genome-scale model we used was closely based on that
published by Beste et al. [6]. We merged Raman et al.’s mycolic
acid submodel [7] into the genome-scale model so that we could
use both models with E-Flux to test for inhibition or enhancement
of mycolic acid production capacity. The merging was done as
follows: we identified all external metabolites of Raman et al.’s
model and found the equivalent metabolite in Beste et al.’s model.
We then removed exchange reactions for these metabolites so that
net production and consumption of these was no longer allowed.
We removed mycolic acid reactions from the genome-scale model
and replaced them with the mycolic acid reactions in Raman et
al.’s model, and normalized the bounds on exchange reactions so
these were uniform (+/21). The net result was to replace
McFadden et al.’s representation of mycolic acids with that of
Raman et al., as the latter is more detailed and as this allows direct
comparison of the results of E-Flux in the two models. The model
is available as Dataset S1.
Expression Data
The expression data published by Boshoff et al. [17] are listed
under GEO accession number GSE1642. Boshoff et al. used
clustering of the expression profiles to predict the mechanisms of
action of previously unknown agents. Data are available for two
channels: Cy3 (control) and Cy5 (condition) on a total of 437
spotted chips, each with mRNA expression data for M.
tuberculosis strain H37Rv. The published data are in log format;
these were exponentiated to obtain raw values. The data of
Karakousis et al. [18] are published at http://www.ncbi.nlm.nih.
gov/geo/ under accession number GSE9776 and are also two-
channel data of H37Rv M. tb; the dataset contains 17 arrays for 6
unique conditions, comparing M. tb’s response to isoniazid in
dormancy models.
Expression Data Processing
We processed the expression data using MAANOVA 2.0 [20], a
Matlab package for analyzing data from two-dye cDNA micro-
array experiments. MAANOVA 2.0 fits an analysis of variance
(ANOVA) model to the data to account for non-biological
variation in the measurements. Briefly, let yijkg denote the log-
transformed measurement from the ith channel, jth chip, kth
variety (experimental condition), and gth gene. Then we fit the
model
yijkg~mijzGgz AG ðÞ jgz DG ðÞ igz^ y ykgzeijkg,
where mij is the average measurement for channel j of chip i, Gg
represents the effect of gene g, (AG)jg represents effects specific to
chip j and gene g, (DG)ig represents effects specific to channel i and
gene g, ^ y ykg represents effects specific to variety k and gene g (i.e. the
biological variation), and eijkg is error. Thus we fit for, and subtract
out, systematic, non-biological effects such as overall brightness
and spot effects. We fit the model such as to minimize the residual
sum of squares (RSS) given by
RSS~
X
i,j,k,g
e2
ijkg:
The estimate of ^ y ykg given by this procedure is used as the
ANOVA-processed data.
We compared the results of our method using ANOVA-
processed data with those using the published values without
statistical filtering. In this approach, the published data (log
format) were exponentiated to obtain raw values. To remove noise
resulting from variation in overall brightness from chip to chip
while preserving median differences between condition and
control channels, we adjusted the medians of each chip according
to the median of that chip’s Cy3 channel. We set the median of all
control channels to the maximum of the control channel medians
across the dataset (rather than a middle value) to avoid obtaining
negative flux constraint inputs. In other words, we computed the
median of each chip’s Cy3 channel (denoted Mj for the j’th chip),
and found the maximum of these, Mmax. We then added (Mmax-
Mj) to both channels of the j’th chip, for each j. The resulting
values had the same median for the Cy3 channels, and different
medians for the Cy5 channels, while the difference between Cy3
and Cy5 channel medians on each chip was the same as in the raw
data. We also performed E-Flux using log-transformed values;
predictions using log-transformed and raw values were correlated
with R=0.99 after the control-channel median adjustment
described here.
Comparing predictions based on ANOVA-processed and raw
expression data (with median adjustment), our results for the top
mycolic acid inhibitors (isoniazid, thiolactomycin, ethionamide)
are preserved, as are the inhibitory predictions for cerulenin, PA-
824 and valinomycin. Ethambutal was also a predicted inhibitor
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streptomycin. The enhancing effect of triclosan was more strongly
predicted from the raw data than the ANOVA-processed data.
ZnSO4 was inhibitory but not as strongly, and GSNO was not as
strongly enhancing. Overall, results from the two data sets were
positively correlated with R=0.62 at a significance level p=2.11e-
48.
For the data on isoniazid and dormancy from Karakousis et al.
[18], the ANOVA model had fewer data points in total (17
microarrays) so the corresponding error bars (see Figure 4) are
wider than for the Boshoff data reflecting a greater residual sum of
squares.
E-Flux Method
The E-Flux method consists of creating constraint vectors a and
b from expression data for control and condition channels, using
these as constraints for flux balance analysis with a given objective,
and comparing the maximum production capacity of that
objective between the control and condition.
We constructed constraint vectors a and b for the control and
condition channels for each condition in the compendium of
expression data as follows. For each reaction that is catalyzed by
only one gene, we set the upper bound bj to the expression value
for the gene whose product catalyzes reaction j, taking the value
from the relevant data. For example, reaction 2 in the mycolic acid
sub-model is catalyzed by gene Rv3279c corresponding to birA
[7], so if the control channel expression value for Rv3279c is 15, b2
is initially set to 15. For each reaction catalyzed by a complex
requiring two genes we set bj to the minimum of the expression of
the two genes, and for reactions which can be catalyzed by either
gene we set bj to the sum of their expression values. We then
normalized the bj values to 1 by dividing each component of bj by
M=maxj (bj). For each exchange reaction, we set aj=21 and
bj=1; in other words, these reactions were not constrained by gene
expression. Changing the constraint (for example, from +/21t o
+/22) on exchange reactions to another value does not change
the results presented here, as the relative production capacity from
control to condition is a log ratio and is not dependent on the
overall scale. Following Raman et al., all internal reactions in the
model were modeled to be irreversible, so that aj=0 for these (j=1
to 219). For the reactions catalyzed by the remaining unknown
gene in Raman’s model we set bj=1 and aj=0.
All of these steps were performed for the control channel
expression data and then separately for the condition channel.
This yields 4 vectors: acontrol and bcontrol taken from the cy3
channel of the chip, and acondition and bcondition taken from the
condition channel. Linear optimization was then performed with
each set of constraints and the same objective function, namely a
weighted production of mycolic acids. The objective function for
the mycolic acid subsystem model was
c~{0:4926 e197{0:2333 e203{0:0327 e209{0:2117 e214{0:0297 e219
where ei represents the vector (0, 0, …, 1, …, 0) with a 1 in the i’th
component and 0 in all other components. Since the linear
programming tool linprog in matlab minimizes c
Tv, the coefficients
of c were chosen to be negative so that the optimization maximizes
(2c
Tv), namely the weighted flux creating mycolic acids. The
reactions included in c produce alpha, cis- and trans- methoxy
mycolate and cis- and trans- keto mycolate respectively. This is the
same as objective function c1 in Raman et al. Our results are
insensitive to the particular balance between the a-, keto- and
methoxy- mycolates in the objective function. In the genome-scale
model our objective function was the same but the reactions are
numbered differently. We also performed E-Flux with two
alternative objective functions: biomass as given in Beste et al.,
and the mycolic acid objective function with the same weights as
given in [7].
This procedure, with either objective function, yields two results
for the maximal production capacity: Pcontrol=max(c
Tv) using
constraints taken from the control channel, and Pcondition=
max(c
Tv) using constraints taken from the condition channel.
The relative production, namely the results shown in Figure 3 and
Supplementary Figures S1, S2, S3, S4 and S5, is given by
log( Pcondition/Pcontrol).
In addition to setting bj equal to the expression value for the
gene catalyzing the j’th reaction, we explored using sigmoidal,
exponential and polynomial increasing functions to create the
constraint b, so that rather than bj=expression(j), we used
bj=f(expression(j)) where f is sigmoidal, exponential or polynomial.
The results presented in Table 1 are robust to saturation at high
expression levels and suppression at low levels, as long as these
retain sufficient variation in the data.
Significance Calculations and Error Bars
To determine whether predictions were significant we resam-
pled the control channel of each chip, adding noise sampled from
the noise distribution given by the Anova model as described
above. We compared the mycolic acid production capacity from
one such resampled control dataset to another, and repeated the
procedure 800 times. We then found the ‘‘null’’ interval in which
95% of the values lie. The interval is denoted by the dotted lines in
Figure 3. Predictions lying within this interval were not considered
significant. To generate the error bars shown in Figure 3, we used
a similar approach. Here, we added noise (again distributed in
accordance with the anova model) to both the control and
condition channel of the chip, and applied E-Flux. After repeating
this procedure 800 times, we found the intervals in which 95% of
the values lay; these form the error bars shown. They represent the
uncertainty in our predictions based on the Anova estimate of how
much random noise there is in the data.
Mycolic Acid Specificity Calculation
To make a distinction between predictions that are specific to
the mycolic acid pathway and those that may result from the
conditions’ effects on a large number of genes in M. tuberculosis,
we used two approaches. For the first, we computed predictions
using randomly chosen genes from each chip in place of the genes
in the metabolic model. To do this, we chose a random
permutation of all genes on each chip, and these randomly chosen
genes (rather than the genes actually listed in the metabolic model)
to form the constraint vectors a and b. This was done for both
control and condition channels of each chip, using the same gene
permutation for the two channels. We then applied E-Flux to
recompute the predicted inhibition or enhancement using
constraints from expression of the randomly selected genes. After
repeating this procedure, we found the range in which 95% of the
resulting predictions lie, for each experiment (grey bars in Figure 3
and Supplementary Figures). Where the range is large, there is
typically substantial overlap between the gene relabelled predic-
tions and the predictions using the correct genes for the metabolic
model. This results from the condition having affected many genes
in the organism. In this case we do not consider the prediction to
be specific to the mycolic acid pathway because there may be
inhibition or enhancement of a number of pathways in the
organism, leading to a likely inhibition when in the model when
random genes are used. Alternatively, where there is considerable
difference between the gene-relabelled predictions and the noise-
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isoniazid (see Figure 3), the predictions of E-Flux are considered
specific to mycolic acids. Our quantitative use of ‘‘specific’’
required that 95% of the noise-resampled predictions (i.e. those
which give the error bars shown in Figure 3) lie outside the 95%
range of the gene-relabelled predictions (grey bars in Figure 3). By
this criterion, when a prediction is deemed ‘‘specific’’ it is unlikely
that that prediction would be obtained with randomly relabelled
genes.
Supporting Information
Figure S1 Predictions of E-flux applied to mycolic acid
biosynthesis in M. tuberculosis. First set in alphabetical order
from the Boshoff expression data compendium.
Found at: doi:10.1371/journal.pcbi.1000489.s001 (3.16 MB TIF)
Figure S2 Predictions of E-flux applied to mycolic acid
biosynthesis in M. tuberculosis. Second set in alphabetical order
from the Boshoff expression data compendium.
Found at: doi:10.1371/journal.pcbi.1000489.s002 (3.16 MB TIF)
Figure S3 Predictions of E-flux applied to mycolic acid
biosynthesis in M. tuberculosis. Third set in alphabetical order
from the Boshoff expression data compendium.
Found at: doi:10.1371/journal.pcbi.1000489.s003 (3.16 MB TIF)
Figure S4 Predictions of E-flux applied to mycolic acid
biosynthesis in M. tuberculosis. Fourth set in alphabetical order
from the Boshoff expression data compendium.
Found at: doi:10.1371/journal.pcbi.1000489.s004 (3.16 MB TIF)
Figure S5 Predictions of E-flux applied to mycolic acid
biosynthesis in M. tuberculosis. Fifth set in alphabetical order
from the Boshoff expression data compendium.
Found at: doi:10.1371/journal.pcbi.1000489.s005 (3.16 MB TIF)
Dataset S1 Integrated genome-scale model in XML format
Found at: doi:10.1371/journal.pcbi.1000489.s006 (1.13 MB
XML)
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